ArticleEClinicalMedicine2020
Individual risk of post-ivermectin serious adverse events in subjects infected with
Article in EClinicalMedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Laboratory diagnosis of loiasis to support individual patient management: A systematic review.PLoS neglected tropical diseases · 2026Pooled it
- Parasitic colitis misdiagnosis as inflammatory bowel disease in high-income settings and association with poor clinical outcomes when exposed to corticosteroids: a systematic review of case reports.BMJ open gastroenterology · 2025Pooled it
- Guideline
- Safety and Short-term Efficacy of a Single Dose of 2 mg Moxidectin inOpen forum infectious diseases · 2024Trial
- Trial
- Efficacy, safety, and tolerability of albendazole and ivermectin based regimens for the treatment of microfilaraemic loiasis in adult patients in Gabon: A randomized controlled assessor blinded clinical trial.PLoS neglected tropical diseases · 2023Trial
- Effect of a single dose of 8 mg moxidectin or 150 μg/kg ivermectin on O. volvulus skin microfilariae in a randomized trial: Differences between areas in the Democratic Republic of the Congo, Liberia and Ghana and impact of intensity of infection.PLoS neglected tropical diseases · 2022Trial
- Assessing diagnostic accuracy of onchocerciasis rapid diagnostic tests using Bayesian latent class models.PLoS neglected tropical diseases · 2026Article
- From the Laboratory to the Field: Assessing the Usability of the NTDscope in the Tropical Rainforest Region of Gabon.The American journal of tropical medicine and hygiene · 2026Article
- Potential of machine learning for prevention and control of neglected tropical diseases: a scoping review.Communications medicine · 2026Article
- HISTONCHO: A dataset of intervention histories for onchocerciasis control & elimination in sub-Saharan Africa.Scientific data · 2026Article
- Article
- Current perspectives in the epidemiology and control of lymphatic filariasis.Clinical microbiology reviews · 2025Review
- Treatment of loiasis: a review of clinical management recommendations.Infectious diseases of poverty · 2025Article
- Revisiting the Loa loa microfilaremia thresholds above which serious adverse events may occur with ivermectin treatment.PLoS neglected tropical diseases · 2025Article
- Eosinophils, basophils and myeloid-derived suppressor cells in chronic Loa loa infection and its treatment in an endemic setting.PLoS neglected tropical diseases · 2024Article
- The pipeline for drugs for control and elimination of neglected tropical diseases: 1. Anti-infective drugs for regulatory registration.Parasites & vectors · 2023Review
- Cases of Loiasis Among a Congolese Family: Screening for Loiasis Among Newly Arrived Refugees From Endemic Areas.The journal for nurse practitioners : JNP · 2023Article
- Characterising co-infections with Plasmodium spp., Mansonella perstans or Loa loa in asymptomatic children, adults and elderly people living on Bioko Island using nucleic acids extracted from malaria rapid diagnostic tests.PLoS neglected tropical diseases · 2022Article
- Onchocerciasis drug development: from preclinical models to humans.Parasitology research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImplementation of onchocerciasis elimination programmes has been delayed in Central Africa because of the risk of ivermectin-related serious adverse events (SAEs) in individuals with high
methodsWe used individual participant data from two trials conducted in loiasis-onchocerciasis co-endemic areas in Cameroon. among the 10 506 ivermectin-treated subjects included in the analysis, 38 (0·36%) developed an ivermectin-related SAE. To predict individual-level risk of SAE, we developed mixed multivariate logistic models including subjects' sex, age, pre-treatment
findingsThe models predicted that regardless of sex, about 1% of people with 20 000
interpretationBy enabling the prediction of post-ivermectin SAE risk in communities with known distribution of
fundingUNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases; Institut de Recherche pour le Développement; Mectizan Donation Program; Bill & Melinda Gates Foundation
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.